Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: Assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide

Journal of Rheumatology

Volumn 39, Issue 4, 2012, Pages 701-706

  Kotyla, Przemyslaw J ^a   Owczarek, Aleksander ^a   Rakoczy, Jaroslaw ^b   Lewicki, Maciej ^a   Kucharz, Eugene J ^a   Emery, Paul ^c,d  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Teaching University Hospital No 7   (Poland)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Endothelin 1; Heart failure; Infliximab; NT pro brain natriuretic peptide; Rheumatoid arthritis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIN 1; INFLIXIMAB; INTERLEUKIN 6;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEART FUNCTION TEST; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84859459736     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110751     Document Type: Article

References (38)

1. Turesson C, Jacobsson L, Bergström U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology 1999;38:668-74. (Pubitemid 29507338)
2. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
3. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: A rheumatological dilemma. Autoimmun Rev 2005;4:153-61. (Pubitemid 40488744)
4. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36-40. (Pubitemid 36077769)
5. Bazzoni F, Beutler B. The tumour necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25. (Pubitemid 26193625)
6. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011;162:785-91.
7. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, et al. TNF alpha blockade in human diseases: An overview of efficacy and safety. Clin Immunol 2008;126:13-30. (Pubitemid 350266448)
8. Sharma R, Anker SD. Immune and neurohormonal pathways in chronic heart failure. Congest Heart Fail 2002;8:23-8. (Pubitemid 34456115)
9. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of Randomised Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602. (Pubitemid 38451714)
10. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomised, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40. (Pubitemid 36793081)
11. Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res 2004;95:1140-53. (Pubitemid 39648205)
12. Giles JT, Fernandes V, Lima JAC, Bathon JM. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther 2005;7:195-207. (Pubitemid 41335156)
13. Kotyla PJ, Kucharz EJ. Who might be predisposed to the development of serious side effects when treated with TNF-alpha antagonist? Clin Exp Rheumatol 2006;24:211. (Pubitemid 43826877)
14. Lim TK, Hayat SA, Gaze D, Celik E, Collinson P, Senior R. Independent value of echocardiography and N-terminal pro natriuretic peptide for the prediction of major outcomes in patients with suspected heart failure. Am J Cardiol 2007;100:870-5. (Pubitemid 47268282)
15. Emdin M, Passino C, Prontera C, Fontana M, Poletti R, Gabutti A, et al. Comparison of brain natriuretic peptide (BNP) and amino-terminal pro BNP for early diagnosis of heart failure. Clin Chem 2007;53:1289-97. (Pubitemid 47020985)
16. Aspromonte N, Ceci V, Chiera A, Coletta C, D'Eri A, Feola M, et al. Rapid brain natriuretic peptide test and Doppler echocardiography for early diagnosis of mild heart failure. Clin Chem 2006;52:1802-8. (Pubitemid 44330717)
17. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Vogt W, Schömig A, et al. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol 2005;95:553-7. (Pubitemid 40255239)
18. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. BMJ 2005;330:625.
19. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: Great expectations or bleak house? Br J Pharmacol 2008;153:1105-19. (Pubitemid 351415492)
20. Birner CM, Ulucan C, Fredersdorf S, Rihm M, Löwel H, Stritzke J, et al. Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: Superiority of BNP. Cytokine 2007;40:89-97. (Pubitemid 350180525)
21. Matsumoto M, Tsujino T, Lee-Kawabata M, Naito Y, Sakoda T, Ohyanagi M, et al. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left systolic dysfunction. Cytokine 2010;49:264-8.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
23. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8. (Pubitemid 16119719)
24. Provan SA, Angel K, Ødegård S, Mowinckel P, Atar D, Kvien TK. The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: A 10 year longitudinal study. Arthritis Res Ther 2008;10:R70.
25. Solus J, Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, et al. Amino-terminal fragment of prohormone brain-type natriuretic peptide (NT-proBNP) in rheumatoid arthritis. Arthritis Rheum 2008;58:2662-9.
26. Peters MJ, Welsh P, McInnes IB, Wolbink G, Dijkmans BA, Sattar N, et al. Tumour necrosis factor α reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: Results from a prospective cohort study. Ann Rheum Dis 2010;69:1281-5.
27. Jug B, Salobir BG, Vene N, Sebestjen M, Sabovic M, Keber I. Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure. Heart Vessels 2009;24:271-6.
28. Tokuda H, Hanai Y, Matsushima-Nishiwaki R, Yamauchi J, Doi T, Harada A, et al. Rho-kinase regulates endothelin-1-stimulated IL-6 synthesis via p38 MAP kinase in osteoblasts. Biochem Biophys Res Commun 2007;362:799-804. (Pubitemid 47390644)
29. Rudominer RL, Roman MJ, Devereux RB, Paget SA, Schwartz JE, Lockshin MD, et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum 2009;60:22-9.
30. Kerekes G, Szekanecz Z, Dér H, Sandor Z, Lakos G, Muszbek L, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: A multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008;35:398-406. (Pubitemid 351374411)
31. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004;63:31-5. (Pubitemid 38064600)
32. Yeboah J, Crouse JR, Bluemke DA, Lima JA, Polak JF, Burke GL, et al. Endothelial dysfunction is associated with left ventricular mass (assessed using MRI) in an adult population (MESA). J Hum Hypertens 2011;25:25-31.
33. Sidiropoulos PI, Siakka P, Pagonidis K, Raptopoulou A, Kritikos H, Tsetis D, et al. Sustained improvement of vascular endothelial function during anti-TNF-alpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009;38:6-10.
34. Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7. (Pubitemid 35222210)
35. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11. (Pubitemid 38230289)
36. Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008;58:667-77. (Pubitemid 351364864)
37. Furian T, Aguiar C, Prado K, Ribeiro RV, Becker L, Martinelli N, et al Ventricular dysfunction and dilation in severe sepsis and septic shock: Relation to endothelial function and mortality. J Crit Care 2011 Aug 18. [E-pub ahead of print]
38. Ciccone MM, Iacoviello M, Puzzovivo A, Scicchitano P, Monitillo F, De Crescenzo F, et al. Clinical correlates of endothelial function in chronic heart failure. Clin Res Cardiol 2011;100:515-21.